D. V. Couanet

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.